On Thursday Cryoport (NASDAQ:CYRX) stock price moved upward at 3.18%. Its total market capitalization is $508265460. Its day lowest price was $13.69 and its hit its day highest price at $14.45. The stock recent volume is 451068 shares in comparison to its average trading volume of 679202 shares. Looking at the stock’s price level on the past 52-week graph, CYRX recorded a 52-week high of $25.02 and its 52-week low of $8.28.
On Nov. 7, 2019, Cryoport (NASDAQ:CYRX) the world’s leading temperature-controlled logistics company dedicated to the life sciences industry, declared financial results for the three and nine-month periods ended September 30, 2019.
Cryoport reported record revenue of $9.6 million for the three-month period ended September 30, 2019, an increase of 81% compared with the same period in the prior year, stated Jerrell Shelton, Chief Executive Officer of Cryoport. This was primarily driven by record revenue from our commercial agreements supporting Gilead’s YESCARTA® and Novartis’ KYMRIAH® which contributed $2.6 million in the Third Quarter of 2019, representing an increase of $2.0 million compared with the Third Quarter of 2018. Notably, this also represents a 39% sequential quarterly increase in revenue over the Second Quarter of 2019. We expect revenue from our commercial agreements to continue to grow and accelerate as the rollouts of these lifesaving therapies continue. We also anticipate that this growth will be supplemented with bluebird bio’s anticipated commercial launch of ZYNTEGLO™ in in early 2020 and followed by others later in the year.